Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) EBIT: 2012-2024

Historic EBIT for Sunshine Biopharma (SBFM) over the last 11 years, with Dec 2024 value amounting to -$5.8 million.

  • Sunshine Biopharma's EBIT rose 1.78% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 31.80%. This contributed to the annual value of -$5.8 million for FY2024, which is 21.46% down from last year.
  • Sunshine Biopharma's EBIT amounted to -$5.8 million in FY2024, which was down 21.46% from -$4.8 million recorded in FY2023.
  • Sunshine Biopharma's EBIT's 5-year high stood at -$576,874 during FY2020, with a 5-year trough of -$27.0 million in FY2022.
  • Over the past 3 years, Sunshine Biopharma's median EBIT value was -$5.8 million (recorded in 2024), while the average stood at -$12.5 million.
  • As far as peak fluctuations go, Sunshine Biopharma's EBIT tumbled by 1,006.53% in 2022, and later spiked by 82.28% in 2023.
  • Yearly analysis of 5 years shows Sunshine Biopharma's EBIT stood at -$576,874 in 2020, then crashed by 322.99% to -$2.4 million in 2021, then plummeted by 1,006.53% to -$27.0 million in 2022, then spiked by 82.28% to -$4.8 million in 2023, then fell by 21.46% to -$5.8 million in 2024.